Two long term stability responses are documented to sorafenib

[Olga]

Thanks to Johannes who found this new article:

Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy.

J Pediatr Hematol Oncol. 2016 Jul;38(5):e169-72. doi: 10.1097/MPH.0000000000000571.
http://www.ncbi.nlm.nih.gov/pubmed/27164526

Kuo DJ1, Menell JS, Glade Bender JL.

BACKGROUND:

Alveolar soft part sarcoma is a rare soft tissue sarcoma that is characterized by a pattern of slow growth with metastases to the lung, bone, and brain that is not responsive to conventional cytotoxic chemotherapy.

OBSERVATIONS:
We describe 2 patients, with a combined 19 years of treatment experience including multiple different chemotherapeutic and targeted therapy regimens, surgery, and radiotherapy. We also present a review of the literature regarding treatment options to highlight recent findings.

CONCLUSIONS:
Alveolar soft part sarcoma is an indolent, but persistently progressive disease. Novel therapeutic agents hold promise in its management.